L-Carnitine intake and high trimethylamine N-oxide plasma levels correlate with low aortic lesions in ApoE-/- transgenic mice expressing CETP

Atherosclerosis

Volumn 244, Issue , 2016, Pages 29-37

  Collins, Heidi L ^a   Drazul Schrader, Denise ^a   Sulpizio, Anthony C ^a   Koster, Paul D ^a   Williamson, Yuping ^b   Adelman, Steven J ^a   Owen, Kevin ^b   Sanli, Toran ^c   Bellamine, Aouatef ^b  

^a Vascular Strategies LLC   (United States)

^b Lonza Inc   (United States)

^c KGK Synergize Inc   (Canada)

Author keywords

Atherosclerosis; Cardiovascular disease; Gut microbiota; L carnitine; TMAO

Indexed keywords

APOLIPOPROTEIN E; CARNITINE; CHOLESTEROL ESTER TRANSFER PROTEIN; LIPID; LIPOPROTEIN; THIAMAZOLE; TRIMETHYLAMINE OXIDE; CETP PROTEIN, HUMAN; METHYLAMINE; TRIMETHYLOXAMINE;

ANIMAL CELL; ANIMAL EXPERIMENT; AORTA ROOT; ARTICLE; ATHEROSCLEROSIS; BLOOD LEVEL; DISEASE COURSE; FOAM CELL; IN VITRO STUDY; IN VIVO STUDY; LIPID BLOOD LEVEL; MACROPHAGE; MALE; MAXIMUM PLASMA CONCENTRATION; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; THORACIC AORTA; TRANSGENIC MOUSE; ANIMAL; BIOSYNTHESIS; BLOOD; CELL CULTURE; DISEASE MODEL; GENETICS; HUMAN; KNOCKOUT MOUSE; METABOLISM; PATHOLOGY;

ANIMALS; APOLIPOPROTEINS E; ATHEROSCLEROSIS; CARNITINE; CELLS, CULTURED; CHOLESTEROL ESTER TRANSFER PROTEINS; DISEASE MODELS, ANIMAL; DISEASE PROGRESSION; HUMANS; MACROPHAGES; MALE; METHYLAMINES; MICE; MICE, KNOCKOUT;

EID: 84946866301     PISSN: 00219150     EISSN: 18791484     Source Type: Journal    
DOI: 10.1016/j.atherosclerosis.2015.10.108     Document Type: Article

References (65)

1. World Health Organization. Cardiovascular diseases (CVDs) Fact Sheet No 317. In: 2011.
2. Copyright World Health Organization. In: 2015. http://www.who.int/cardiovascular_diseases/en/.
3. Alexander R.W. Theodore Cooper Memorial Lecture. Hypertension and the pathogenesis of atherosclerosis. Oxidative stress and the mediation of arterial inflammatory response: a new perspective. Hypertension 1995, 25:155-161.
4. Beckman J.A., Creager M.A., Libby P. Diabetes and atherosclerosis: epidemiology, pathophysiology, and management. JAMA 2002, 287:2570-2581.
5. Nabel E.G. Cardiovascular disease. N. Engl. J. Med. 2003, 349:60-72.
6. Das U.N. Nutritional factors in the prevention and management of coronary artery disease and heart failure. Nutrition 2015, 31:283-291.
7. Ussher J.R., Lopaschuk G.D., Arduini A. Gut microbiota metabolism of L-carnitine and cardiovascular risk. Atherosclerosis 2013, 231:456-461.
8. Koeth R.A., Wang Z., Levison B.S., Buffa J.A., Org E., Sheehy B.T., et al. Intestinal microbiota metabolism of L-carnitine, a nutrient in red meat, promotes atherosclerosis. Nat. Med. 2013, 19:576-585.
9. Howitt M.R., Garrett W.S. A complex microworld in the gut: gut microbiota and cardiovascular disease connectivity. Nat. Med. 2012, 18:1188-1189.
10. Stock J. Gut microbiota: an environmental risk factor for cardiovascular disease. Atherosclerosis 2013, 229:440-442.
11. Drosos I., Tavridou A., Kolios G. New aspects on the metabolic role of intestinal microbiota in the development of atherosclerosis. Metabolism 2015, 64:476-481.
12. Lozupone C.A., Stombaugh J.I., Gordon J.I., Jansson J.K., Knight R. Diversity, stability and resilience of the human gut microbiota. Nature 2012, 489:220-230.
13. Gill S.R., Pop M., Deboy R.T., Eckburg P.B., Turnbaugh P.J., Samuel B.S., et al. Metagenomic analysis of the human distal gut microbiome. Science 2006, 312:1355-1359.
14. Qin J., Li R., Raes J., Arumugam M., Burgdorf K.S., Manichanh C., et al. A human gut microbial gene catalogue established by metagenomic sequencing. Nature 2010, 464:59-65.
15. Laparra J.M., Sanz Y. Interactions of gut microbiota with functional food components and nutraceuticals. Pharmacol. Res. 2010, 61:219-225.
16. Marques T.M., Wall R., Ross R.P., Fitzgerald G.F., Ryan C.A., Stanton C. Programming infant gut microbiota: influence of dietary and environmental factors. Curr. Opin. Biotechnol. 2010, 21:149-156.
17. Burcelin R., Serino M., Chabo C., Blasco-Baque V., Amar J. Gut microbiota and diabetes: from pathogenesis to therapeutic perspective. Acta Diabetol. 2011, 48:257-273.
18. Huang Y.J., Boushey H.A. The microbiome in asthma. J. Allergy Clin. Immunol. 2015, 135:25-30.
19. Miller M.J. Risk factors for cardiovascular disease: a cautionary tale of diet-microbiome interactions. J. Am. Coll. Nutr. 2013, 32:75-78.
20. Sun J., Chang E.B. Exploring gut microbes in human health and disease: pushing the envelope. Genes Dis. 2014, 1:132-139.
21. Tang W.H., Hazen S.L. The contributory role of gut microbiota in cardiovascular disease. J. Clin. Invest. 2014, 124:4204-4211.
22. Wang Z., Klipfell E., Bennett B.J., Koeth R., Levison B.S., Dugar B., et al. Gut flora metabolism of phosphatidylcholine promotes cardiovascular disease. Nature 2011, 472:57-63.
23. Arduini A., Bonomini M., Savica V., Amato A., Zammit V. Carnitine in metabolic disease: potential for pharmacological intervention. Pharmacol. Ther. 2008, 120:149-156.
24. Sayed-Ahmed M.M., Khattab M.M., Gad M.Z., Mostafa N. L-carnitine prevents the progression of atherosclerotic lesions in hypercholesterolaemic rabbits. Pharmacol. Res. 2001, 44:235-242.
25. DiNicolantonio J.J., Lavie C.J., Fares H., Menezes A.R., O'Keefe J.H. L-carnitine in the secondary prevention of cardiovascular disease: systematic review and meta-analysis. Mayo Clin. Proc. 2013, 88:544-551.
26. Tang W.H., Wang Z., Levison B.S., Koeth R.A., Britt E.B., Fu X., et al. Intestinal microbial metabolism of phosphatidylcholine and cardiovascular risk. N. Engl. J. Med. 2013, 368:1575-1584.
27. Wang Z., Tang W.H., Buffa J.A., Fu X., Britt E.B., Koeth R.A., et al. Prognostic value of choline and betaine depends on intestinal microbiota-generated metabolite trimethylamine-N-oxide. Eur. Heart J. 2014, 35:904-910.
28. Bennett B.J., de Aguiar Vallim T.Q., Wang Z., Shih D.M., Meng Y., Gregory J., et al. Trimethylamine-N-oxide, a metabolite associated with atherosclerosis, exhibits complex genetic and dietary regulation. Cell Metab. 2013, 17:49-60.
29. Withers P., Hefter G., Pang T.S. Role of urea and methylamines in buoyancy of elasmobranchs. J. Exp. Biol. 1994, 188:175-189.
30. Barter P.J., Brewer H.B., Chapman M.J., Hennekens C.H., Rader D.J., Tall A.R. Cholesteryl ester transfer protein: a novel target for raising HDL and inhibiting atherosclerosis. Arterioscler. Thromb. Vasc. Biol. 2003, 23:160-167.
31. Koeth R.A., Levison B.S., Culley M.K., Buffa J.A., Wang Z., Gregory J.C., et al. gamma-Butyrobetaine is a proatherogenic intermediate in gut microbial metabolism of L-carnitine to TMAO. Cell Metab. 2014, 20:799-812.
32. Marotti K.R., Castle C.K., Boyle T.P., Lin A.H., Murray R.W., Melchior G.W. Severe atherosclerosis in transgenic mice expressing simian cholesteryl ester transfer protein. Nature 1993, 364:73-75.
33. Plump A.S., Masucci-Magoulas L., Bruce C., Bisgaier C.L., Breslow J.L., Tall A.R. Increased atherosclerosis in ApoE and LDL receptor gene knock-out mice as a result of human cholesteryl ester transfer protein transgene expression. Arterioscler. Thromb. Vasc. Biol. 1999, 19:1105-1110.
34. de H.W., van der Hoogt C.C., Westerterp M., Hoekstra M., Dallinga-Thie G.M., Princen H.M., et al. Atorvastatin increases HDL cholesterol by reducing CETP expression in cholesterol-fed APOE*3-Leiden.CETP mice. Atherosclerosis 2008, 197:57-63.
35. van der Hoorn J.W., de H.W., Berbee J.F., Havekes L.M., Jukema J.W., Rensen P.C., et al. Niacin increases HDL by reducing hepatic expression and plasma levels of cholesteryl ester transfer protein in APOE*3Leiden.CETP mice. Arterioscler. Thromb. Vasc. Biol. 2008, 28:2016-2022.
36. Llera-Moya M., Drazul-Schrader D., Asztalos B.F., Cuchel M., Rader D.J., Rothblat G.H. The ability to promote efflux via ABCA1 determines the capacity of serum specimens with similar high-density lipoprotein cholesterol to remove cholesterol from macrophages. Arterioscler. Thromb. Vasc. Biol. 2010, 30:796-801.
37. Markwell M.A., Haas S.M., Bieber L.L., Tolbert N.E. A modification of the Lowry procedure to simplify protein determination in membrane and lipoprotein samples. Anal. Biochem. 1978, 87:206-210.
38. Tanigawa H., Billheimer J.T., Ji Tohyama, Zhang Y., Rothblat G., Rader D.J. Expression of cholesteryl ester transfer protein in mice promotes macrophage reverse cholesterol transport. Circulation 2007, 116:1267-1273.
39. Tangirala R.K., Rubin E.M., Palinski W. Quantitation of atherosclerosis in murine models: correlation between lesions in the aortic origin and in the entire aorta, and differences in the extent of lesions between sexes in LDL receptor-deficient and apolipoprotein E-deficient mice. J. Lipid Res. 1995, 36:2320-2328.
40. Bligh E.G., Dyer W.J. A rapid method of total lipid extraction and purification. Can. J. Biochem. Physiol. 1959, 37:911-917.
41. Greaves D.R., Gordon S. The macrophage scavenger receptor at 30 years of age: current knowledge and future challenges. J. Lipid Res. 2009, 50. Suppl:S282-S286.
42. Jones N.L., Reagan J.W., Willingham M.C. The pathogenesis of foam cell formation: modified LDL stimulates uptake of co-incubated LDL via macropinocytosis. Arterioscler. Thromb. Vasc. Biol. 2000, 20:773-781.
43. Libby P. Inflammation in atherosclerosis. Nature 2002, 420:868-874.
44. Yu X.H., Fu Y.C., Zhang D.W., Yin K., Tang C.K. Foam cells in atherosclerosis. Clin. Chim. Acta 2013, 424:245-252.
45. Xie F., Zhou X., Genter M.B., Behr M., Gu J., Ding X. The tissue-specific toxicity of methimazole in the mouse olfactory mucosa is partly mediated through target-tissue metabolic activation by CYP2A5. Drug Metab. Dispos. 2011, 39:947-951.
46. Guo Z., Raeissi S., White R.B., Stevens J.C. Orphenadrine and methimazole inhibit multiple cytochrome P450 enzymes in human liver microsomes. Drug Metab. Dispos. 1997, 25:390-393.
47. Lagorce J.F., Moulard T., Rousseau A., Comby F., Buxeraud J., Raby C. Anti-inflammatory action of methimazole. Pharmacology 1997, 55:173-178.
48. Sewerynek J., Wiktorska J., Nowak D., Lewinski A. Methimazole protection against oxidative stress induced by hyperthyroidism in Graves disease. Endocr. Regul. 2000, 34:83-89.
49. Bell F.P., Raymond T.L., Patnode C.L. The influence of diet and carnitine supplementation on plasma carnitine, cholesterol and triglyceride in WHHL (Watanabe-heritable hyperlipidemic), Netherland dwarf and New Zealand rabbits (Oryctolagus cuniculus). Comp. Biochem. Physiol. B 1987, 87:587-591.
50. Pistone G., Marino A., Leotta C., Dell'Arte S., Finocchiaro G., Malaguarnera M. Levocarnitine administration in elderly subjects with rapid muscle fatigue: effect on body composition, lipid profile and fatigue. Drugs Aging 2003, 20:761-767.
51. Gulewitsch W. Zur Kenntnis der Extraktionsstoffe der Muskeln. 2. Mitteilungenüber das Carnitin (extracted substances in muscle, report on carnitine). Physiol. Chem. 1905, 45.
52. Rospond B., Chlopicka J. [The biological function of L-carnitine and its content in the particular food examples]. Przegl Lek. 2013, 70:85-91.
53. Karlic H., Lohninger A. Supplementation of L-carnitine in athletes: does it make sense?. Nutrition 2004, 20:709-715.
54. Opie L.H. Role of carnitine in fatty acid metabolism of normal and ischemic myocardium. Am. Heart J. 1979, 97:375-388.
55. Bellamine A. TMAO Treatment Does Not Affect Foam Cell Formation (Cholesterol Mass Loading) and Cholesterol Efflux in J774 Mouse Macrophage 2014, Experimental Biology, San Diego.
56. Makhija L., Krishnan V., Rehman R., Chakraborty S., Maity S., Mabalirajan U., et al. Chemical chaperones mitigate experimental asthma by attenuating endoplasmic reticulum stress. Am. J. Respir. Cell Mol. Biol. 2014, 50:923-931.
57. Mello C.C., Barrick D. Measuring the stability of partly folded proteins using TMAO. Protein Sci. 2003, 12:1522-1529.
58. Gong B., Zhang L.Y., Pang C.P., Lam D.S., Yam G.H. Trimethylamine N-oxide alleviates the severe aggregation and ER stress caused by G98R alphaA-crystallin. Mol. Vis. 2009, 15:2829-2840.
59. Falls J.G., Blake B.L., Cao Y., Levi P.E., Hodgson E. Gender differences in hepatic expression of flavin-containing monooxygenase isoforms (FMO1, FMO3, and FMO5) in mice. J. Biochem. Toxicol. 1995, 10:171-177.
60. Falls J.G., Ryu D.Y., Cao Y., Levi P.E., Hodgson E. Regulation of mouse liver flavin-containing monooxygenases 1 and 3 by sex steroids. Arch. Biochem. Biophys. 1997, 342:212-223.
61. Jawien J., Toton-Zuranska J., Kus K., Pawlowska M., Olszanecki R., Korbut R. The effect of AVE 0991, nebivolol and doxycycline on inflammatory mediators in an apoE-knockout mouse model of atherosclerosis. Med. Sci. Monit. 2012, 18:BR389-BR393.
62. Madan M., Bishayi B., Hoge M., Messas E., Amar S. Doxycycline affects diet- and bacteria-associated atherosclerosis in an ApoE heterozygote murine model: cytokine profiling implications. Atherosclerosis 2007, 190:62-72.
63. Spagnoli L.G., Orlandi A., Marino B., Mauriello A., De A.C., Ramacci M.T. Propionyl-L-carnitine prevents the progression of atherosclerotic lesions in aged hyperlipemic rabbits. Atherosclerosis 1995, 114:29-44.
64. Turkanoglu O.A., Can D.B., Demirkaya S., Adali O. Flavin containing monooxygenase 3 genetic polymorphisms Glu158Lys and Glu308Gly and their relation to ischemic stroke. Gene 2013, 521:116-121.
65. Fukami K., Yamagishi S., Sakai K., Kaida Y., Yokoro M., Ueda S., et al. Oral L-carnitine supplementation increases trimethylamine-N-oxide but reduces markers of vascular injury in hemodialysis patients. J. Cardiovasc Pharmacol. 2015, 65:289-295.